Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP–IPV) vaccine
Matthew F. Daley(Kaiser Permanente), Eric Weintraub, Nicola P. Klein, Jennifer C. Nelson(Kaiser Permanente Washington Health Research Institute), James D. Nordin(HealthPartners), Komal J. Narwaney(Kaiser Permanente), Simon J. Hambidge, Lin Li(Harbin University of Commerce), W. Katherine Yih(Harvard University), Jason M. Glanz(Kaiser Permanente), Ruihua Yin(Qingdao University), Steven J. Jacobsen(Mayo Clinic)
Cited by 39
Related Papers
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
|New England Journal of Medicine|2021|937
Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration — United States, 2020
|MMWR Morbidity and Mortality Weekly Report|2020|720
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602